Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001104659-23-090702
Filing Date
2023-08-14
Accepted
2023-08-11 21:12:00
Documents
17
Period of Report
2023-07-21
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A tm2323141d1_8ka.htm   iXBRL 8-K/A 35864
2 EXHIBIT 23.2 tm2323141d1_ex23-2.htm EX-23.2 3549
3 EXHIBIT 99.7 tm2323141d1_ex99-7.htm EX-99.7 626538
4 EXHIBIT 99.8 tm2323141d1_ex99-8.htm EX-99.8 188428
5 EXHIBIT 99.9 tm2323141d1_ex99-9.htm EX-99.9 262261
  Complete submission text file 0001104659-23-090702.txt   1482217

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA aeon-20230721.xsd EX-101.SCH 3369
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aeon-20230721_def.xml EX-101.DEF 26589
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE aeon-20230721_lab.xml EX-101.LAB 36481
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aeon-20230721_pre.xml EX-101.PRE 25213
11 EXTRACTED XBRL INSTANCE DOCUMENT tm2323141d1_8ka_htm.xml XML 6198
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-40021 | Film No.: 231165883
SIC: 2834 Pharmaceutical Preparations